The Ubiquitin Carboxyl Terminal Hydrolase 7 pipeline drugs market research report outlays comprehensive information on the Ubiquitin Carboxyl Terminal Hydrolase 7 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Ubiquitin Carboxyl Terminal Hydrolase 7 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Oncology which include the indications Unspecified Cancer, and Oncology. It also reviews key players involved in Ubiquitin Carboxyl Terminal Hydrolase 7 targeted therapeutics development with respective active and dormant or discontinued products.
The Ubiquitin Carboxyl Terminal Hydrolase 7 pipeline targets constitutes close to six molecules. Out of which, approximately four molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 3, and 1 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 1 molecule.
Ubiquitin Carboxyl Terminal Hydrolase 7 overview
Ubiquitin Carboxyl Terminal Hydrolase 7 is an enzyme that in humans is encoded by a gene USP7. This is also known as ubiquitin carboxyl-terminal hydrolase 7 or herpesvirus-associated ubiquitin-specific protease (HAUSP). It belongs to the peptidase C19 family, which includes ubiquitinyl hydrolases. USP7 deubiquitinates target proteins such as p53 (a tumor suppressor protein) and WASH (essential for endosomal protein recycling), and regulates their activities by counteracting the opposing ubiquitin ligase activity of proteins such as HDM2 and TRIM27, involved in the respective process. Mutations in this gene have been implicated in a neurodevelopmental disorder.
For a complete picture of Ubiquitin Carboxyl Terminal Hydrolase 7’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.